Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$21.88 -0.6%	$21.18	$17.24 ▼ $28.56	$14.12B	0.94	1.25 million shs	837,917 shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$70.90 ▼ $131.98	$14.05B	0.69	1.56 million shs	N/A
PCVX Vaxcyte	$36.21 -3.1%	$33.84	$27.66 ▼ $121.06	$4.82B	1.19	1.49 million shs	1.19 million shs
SMMT Summit Therapeutics	$26.20 -5.2%	$22.82	$8.71 ▼ $36.91	$20.52B	-1.01	3.76 million shs	3.00 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	-0.59%	+2.24%	+1.48%	+9.18%	-18.45%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+72.36%
PCVX Vaxcyte	-3.10%	+0.78%	+8.41%	+18.14%	-55.50%
SMMT Summit Therapeutics	-5.18%	+4.80%	+29.96%	+6.46%	+181.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	4.0179 of 5 stars	3.3	5.0	0.0	3.2	0.0	3.1
ITCI Intra-Cellular Therapies	0.9597 of 5 stars	1.1	0.0	4.5	1.3	1.7	0.6
PCVX Vaxcyte	1.8294 of 5 stars	3.6	1.0	0.0	2.5	1.7	0.0
SMMT Summit Therapeutics	3.0832 of 5 stars	4.4	3.0	0.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	72.76% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
PCVX Vaxcyte	3.10	Buy	$136.50	276.97% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	32.32% Upside

Current Analyst Ratings Breakdown

Latest PCVX, SMMT, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.50	$1.51 per share	14.52	$8.04 per share	2.72
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
SMMT Summit Therapeutics	$700K	27,797.08	N/A	N/A	$0.53 per share	49.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	12.43	12.29	6.69	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)

Latest PCVX, SMMT, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GMAB Genmab A/S	$0.39	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PCVX Vaxcyte	-$1.12	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
PCVX Vaxcyte	N/A	17.70	17.70
SMMT Summit Therapeutics	N/A	10.63	10.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
PCVX Vaxcyte	96.78%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
PCVX Vaxcyte	3.10%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable

PCVX, SMMT, ITCI, and GMAB Headlines

Recent News About These Companies

Principal Financial Group Inc. Has $4.75 Million Stock Holdings in Summit Therapeutics PLC (NASDAQ:SMMT)

July 18 at 3:15 AM | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 17 at 10:53 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 17 at 10:00 AM | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?

July 16 at 1:00 PM | marketbeat.com

Florida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)

July 15, 2025 | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 12, 2025 | prnewswire.com

12,025 Shares in Summit Therapeutics PLC (NASDAQ:SMMT) Purchased by U.S. Capital Wealth Advisors LLC

July 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (SMMT) Stock Price Today - WSJ

July 10, 2025 | wsj.com

Summit Therapeutics (NASDAQ:SMMT) Trading 7.6% Higher - Here's Why

July 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 7, 2025 | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why

July 7, 2025 | marketbeat.com

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

July 7, 2025 | zacks.com

Summit Therapeutics Inc. (SMMT) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

2 Soaring Stocks With More Upside Potential to Buy and Hold

July 4, 2025 | fool.com

AstraZeneca in talks with Summit for over $15 billion license deal

July 4, 2025 | thepharmaletter.comT

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

July 3, 2025 | msn.com

Summit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZeneca

July 3, 2025 | msn.com

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

July 3, 2025 | msn.com

Why Summit Therapeutics Stock Soared 8% Higher Today

July 3, 2025 | fool.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCVX, SMMT, ITCI, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$21.88 -0.13 (-0.59%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$21.92 +0.05 (+0.21%)

As of 07/18/2025 07:11 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Vaxcyte NASDAQ:PCVX

$36.21 -1.16 (-3.10%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$36.25 +0.04 (+0.11%)

As of 07/18/2025 04:42 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Summit Therapeutics NASDAQ:SMMT

$26.20 -1.43 (-5.18%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.36 +0.16 (+0.60%)

As of 07/18/2025 07:58 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time